Neuropharmacology And Neurochemistry Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Neuropharmacology and Neurochemistry

Neuropharmacology refers to the study of the effects of drugs on the nervous system, this field involve the study and research on the actions of medications for psychiatric and neurologic disorders as well as those of drugs of abuse. Neuropharmacology also uses drugs as tools for better understanding of normal nervous system functioning. The main objective of neuropharmacology is to apply mechanisms of drugs to develop effective treatments and preventive measures for nervous system abnormalities. It helps to understand how drugs affect cellular function in the nervous system. Behavioral and molecular are the two different parts of neuropharmacology . Behavioral neuropharmacology focuses on the study of how drugs affect human behavior and molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with an aim of developing drugs that helps in improving neurological function.

The study of neurotransmitters, psychopharmaceuticals and neuropeptides, that control and influence the physiology of the nervous system is known as Neurochemistry. Research in this field is focused on the biochemistry and molecular biology of organic compounds in the nervous system, and their roles in neural processes like cortical plasticity, neurogenesis, and neural differentiation. Neurochemicals are basically oxytocin, serotonin, dopamine and other neurotransmitters and neurotransmitter-regulating substances. This particular field investigates how neurochemicals influence the operation of neurons, synapses, and neural networks.

Market Analysis: The markets for neuropharmacology and neurochemistry are set for strong growth from 2025 to 2030, with a positive compound annual growth rate (CAGR) driven by the rising prevalence of neurological disorders, an aging population, and increased R&D. The broader CNS therapeutics market is expected to grow at a CAGR of about 6.5%, while the overall neuroscience market is projected to see a CAGR of around 5.6% to 6.18%. A more specific segment, the neurological disorder drugs market, is anticipated to grow at a CAGR of 4.5% between 2025 and 2031. This expansion is further fueled by technological advancements that are leading to more effective and targeted treatments.

Tracks